JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
NCT04951947
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Small-cell Lung Cancer
Interventions
DRUG:
JS201 combine with Lenvatinib
Sponsor
Hunan Province Tumor Hospital